EMEA (Europe, Middle East and Africa) Cancer Monoclonal Antibodies Market Report 2017

August 2017 | 110 pages | ID: E9A47506A57EN
QYResearch

Abstracts

In this report, the EMEA Cancer Monoclonal Antibodies market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Units), revenue (Million USD), market share and growth rate of Cancer Monoclonal Antibodies for these regions, from 2012 to 2022 (forecast)

• Europe: Germany, France, UK, Russia, Italy and Benelux;
• Middle East: Saudi Arabia, Israel, UAE and Iran;
• Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Cancer Monoclonal Antibodies market competition by top manufacturers/players, with Cancer Monoclonal Antibodies sales volume (K Units), price (USD/Unit), revenue (Million USD) and market share for each manufacturer/player; the top players including

• F. Hoffmann-La Roche
• Amgen
• Bristol-Myers Squibb
• Takeda Pharmaceuticals
• Pfizer
• Merck
• Eli Lilly
• Sanofi
• Janssen Biotech
• Novartis
• AbbVie
• Boehringer Ingelheim
• AstraZeneca
• Bayer
• Biogen
• TG Therapeutics
• CTI BioPharma
• Intas Pharmaceuticals
• Kyowa Hakko Kirin

On the basis of product, this report displays the sales volume (K Units), revenue (Million USD), product price (USD/Unit), market share and growth rate of each type, primarily split into

• Naked mAbs
• Conjugated mAbs

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (K Units), market share and growth rate of Cancer Monoclonal Antibodies for each application, including

• Hospitals
• Retail Pharmacies

If you have any special requirements, please let us know and we will offer you the report as you want.

Contents

EMEA (Europe, Middle East and Africa) Cancer Monoclonal Antibodies Market Report 2017

1 CANCER MONOCLONAL ANTIBODIES OVERVIEW

1.1 Product Overview and Scope of Cancer Monoclonal Antibodies
1.2 Classification of Cancer Monoclonal Antibodies
  1.2.1 EMEA Cancer Monoclonal Antibodies Market Size (Sales) Comparison by Type (2012-2022)
  1.2.2 EMEA Cancer Monoclonal Antibodies Market Size (Sales) Market Share by Type (Product Category) in 2016
  1.2.3 Naked mAbs
  1.2.4 Conjugated mAbs
1.3 EMEA Cancer Monoclonal Antibodies Market by Application/End Users
  1.3.1 EMEA Cancer Monoclonal Antibodies Sales (Volume) and Market Share Comparison by Application (2012-2022
  1.3.2 Hospitals
  1.3.3 Retail Pharmacies
1.4 EMEA Cancer Monoclonal Antibodies Market by Region
  1.4.1 EMEA Cancer Monoclonal Antibodies Market Size (Value) Comparison by Region (2012-2022)
  1.4.2 Europe Status and Prospect (2012-2022)
  1.4.3 Middle East Status and Prospect (2012-2022)
  1.4.4 Africa Status and Prospect (2012-2022)
1.5 EMEA Market Size (Value and Volume) of Cancer Monoclonal Antibodies (2012-2022)
  1.5.1 EMEA Cancer Monoclonal Antibodies Sales and Growth Rate (2012-2022)
  1.5.2 EMEA Cancer Monoclonal Antibodies Revenue and Growth Rate (2012-2022)

2 EMEA CANCER MONOCLONAL ANTIBODIES COMPETITION BY MANUFACTURERS/PLAYERS/SUPPLIERS, REGION, TYPE AND APPLICATION

2.1 EMEA Cancer Monoclonal Antibodies Market Competition by Players/Manufacturers
  2.1.1 EMEA Cancer Monoclonal Antibodies Sales Volume and Market Share of Major Players (2012-2017)
  2.1.2 EMEA Cancer Monoclonal Antibodies Revenue and Share by Players (2012-2017)
  2.1.3 EMEA Cancer Monoclonal Antibodies Sale Price by Players (2012-2017)
2.2 EMEA Cancer Monoclonal Antibodies (Volume and Value) by Type/Product Category
  2.2.1 EMEA Cancer Monoclonal Antibodies Sales and Market Share by Type (2012-2017)
  2.2.2 EMEA Cancer Monoclonal Antibodies Revenue and Market Share by Type (2012-2017)
  2.2.3 EMEA Cancer Monoclonal Antibodies Sale Price by Type (2012-2017)
2.3 EMEA Cancer Monoclonal Antibodies (Volume) by Application
2.4 EMEA Cancer Monoclonal Antibodies (Volume and Value) by Region
  2.4.1 EMEA Cancer Monoclonal Antibodies Sales and Market Share by Region (2012-2017)
  2.4.2 EMEA Cancer Monoclonal Antibodies Revenue and Market Share by Region (2012-2017)
  2.4.3 EMEA Cancer Monoclonal Antibodies Sales Price by Region (2012-2017)

3 EUROPE CANCER MONOCLONAL ANTIBODIES (VOLUME, VALUE AND SALES PRICE), BY PLAYERS, COUNTRIES, TYPE AND APPLICATION

3.1 Europe Cancer Monoclonal Antibodies Sales and Value (2012-2017)
  3.1.1 Europe Cancer Monoclonal Antibodies Sales Volume and Growth Rate (2012-2017)
  3.1.2 Europe Cancer Monoclonal Antibodies Revenue and Growth Rate (2012-2017)
3.2 Europe Cancer Monoclonal Antibodies Sales and Market Share by Type
3.3 Europe Cancer Monoclonal Antibodies Sales and Market Share by Application
3.4 Europe Cancer Monoclonal Antibodies Sales Volume and Value (Revenue) by Countries
  3.4.1 Europe Cancer Monoclonal Antibodies Sales Volume by Countries (2012-2017)
  3.4.2 Europe Cancer Monoclonal Antibodies Revenue by Countries (2012-2017)
  3.4.3 Germany Cancer Monoclonal Antibodies Sales and Growth Rate (2012-2017)
  3.4.4 France Cancer Monoclonal Antibodies Sales and Growth Rate (2012-2017)
  3.4.5 UK Cancer Monoclonal Antibodies Sales and Growth Rate (2012-2017)
  3.4.6 Russia Cancer Monoclonal Antibodies Sales and Growth Rate (2012-2017)
  3.4.7 Italy Cancer Monoclonal Antibodies Sales and Growth Rate (2012-2017)
  3.4.8 Benelux Cancer Monoclonal Antibodies Sales and Growth Rate (2012-2017)

4 MIDDLE EAST CANCER MONOCLONAL ANTIBODIES (VOLUME, VALUE AND SALES PRICE), BY REGION, TYPE AND APPLICATION

4.1 Middle East Cancer Monoclonal Antibodies Sales and Value (2012-2017)
  4.1.1 Middle East Cancer Monoclonal Antibodies Sales Volume and Growth Rate (2012-2017)
  4.1.2 Middle East Cancer Monoclonal Antibodies Revenue and Growth Rate (2012-2017)
4.2 Middle East Cancer Monoclonal Antibodies Sales and Market Share by Type
4.3 Middle East Cancer Monoclonal Antibodies Sales and Market Share by Application
4.4 Middle East Cancer Monoclonal Antibodies Sales Volume and Value (Revenue) by Countries
  4.4.1 Middle East Cancer Monoclonal Antibodies Sales Volume by Countries (2012-2017)
  4.4.2 Middle East Cancer Monoclonal Antibodies Revenue by Countries (2012-2017)
  4.4.3 Saudi Arabia Cancer Monoclonal Antibodies Sales and Growth Rate (2012-2017)
  4.4.4 Israel Cancer Monoclonal Antibodies Sales and Growth Rate (2012-2017)
  4.4.5 UAE Cancer Monoclonal Antibodies Sales and Growth Rate (2012-2017)
  4.4.6 Iran Cancer Monoclonal Antibodies Sales and Growth Rate (2012-2017)

5 AFRICA CANCER MONOCLONAL ANTIBODIES (VOLUME, VALUE AND SALES PRICE) BY PLAYERS, COUNTRIES, TYPE AND APPLICATION

5.1 Africa Cancer Monoclonal Antibodies Sales and Value (2012-2017)
  5.1.1 Africa Cancer Monoclonal Antibodies Sales Volume and Growth Rate (2012-2017)
  5.1.2 Africa Cancer Monoclonal Antibodies Revenue and Growth Rate (2012-2017)
5.2 Africa Cancer Monoclonal Antibodies Sales and Market Share by Type
5.3 Africa Cancer Monoclonal Antibodies Sales and Market Share by Application
5.4 Africa Cancer Monoclonal Antibodies Sales Volume and Value (Revenue) by Countries
  5.4.1 Africa Cancer Monoclonal Antibodies Sales Volume by Countries (2012-2017)
  5.4.2 Africa Cancer Monoclonal Antibodies Revenue by Countries (2012-2017)
  5.4.3 South Africa Cancer Monoclonal Antibodies Sales and Growth Rate (2012-2017)
  5.4.4 Nigeria Cancer Monoclonal Antibodies Sales and Growth Rate (2012-2017)
  5.4.5 Egypt Cancer Monoclonal Antibodies Sales and Growth Rate (2012-2017)
  5.4.6 Algeria Cancer Monoclonal Antibodies Sales and Growth Rate (2012-2017)

6 EMEA CANCER MONOCLONAL ANTIBODIES MANUFACTURERS/PLAYERS PROFILES AND SALES DATA

6.1 F. Hoffmann-La Roche
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Cancer Monoclonal Antibodies Product Type, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 F. Hoffmann-La Roche Cancer Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 Amgen
  6.2.1 Company Basic Information, Manufacturing Base and Competitors
  6.2.2 Cancer Monoclonal Antibodies Product Type, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 Amgen Cancer Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview
6.3 Bristol-Myers Squibb
  6.3.1 Company Basic Information, Manufacturing Base and Competitors
  6.3.2 Cancer Monoclonal Antibodies Product Type, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 Bristol-Myers Squibb Cancer Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Main Business/Business Overview
6.4 Takeda Pharmaceuticals
  6.4.1 Company Basic Information, Manufacturing Base and Competitors
  6.4.2 Cancer Monoclonal Antibodies Product Type, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 Takeda Pharmaceuticals Cancer Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Main Business/Business Overview
6.5 Pfizer
  6.5.1 Company Basic Information, Manufacturing Base and Competitors
  6.5.2 Cancer Monoclonal Antibodies Product Type, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 Pfizer Cancer Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Main Business/Business Overview
6.6 Merck
  6.6.1 Company Basic Information, Manufacturing Base and Competitors
  6.6.2 Cancer Monoclonal Antibodies Product Type, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 Merck Cancer Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2012-2017)
  6.6.4 Main Business/Business Overview
6.7 Eli Lilly
  6.7.1 Company Basic Information, Manufacturing Base and Competitors
  6.7.2 Cancer Monoclonal Antibodies Product Type, Application and Specification
    6.7.2.1 Product A
    6.7.2.2 Product B
  6.7.3 Eli Lilly Cancer Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2012-2017)
  6.7.4 Main Business/Business Overview
6.8 Sanofi
  6.8.1 Company Basic Information, Manufacturing Base and Competitors
  6.8.2 Cancer Monoclonal Antibodies Product Type, Application and Specification
    6.8.2.1 Product A
    6.8.2.2 Product B
  6.8.3 Sanofi Cancer Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2012-2017)
  6.8.4 Main Business/Business Overview
6.9 Janssen Biotech
  6.9.1 Company Basic Information, Manufacturing Base and Competitors
  6.9.2 Cancer Monoclonal Antibodies Product Type, Application and Specification
    6.9.2.1 Product A
    6.9.2.2 Product B
  6.9.3 Janssen Biotech Cancer Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2012-2017)
  6.9.4 Main Business/Business Overview
6.10 Novartis
  6.10.1 Company Basic Information, Manufacturing Base and Competitors
  6.10.2 Cancer Monoclonal Antibodies Product Type, Application and Specification
    6.10.2.1 Product A
    6.10.2.2 Product B
  6.10.3 Novartis Cancer Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2012-2017)
  6.10.4 Main Business/Business Overview
6.11 AbbVie
6.12 Boehringer Ingelheim
6.13 AstraZeneca
6.14 Bayer
6.15 Biogen
6.16 TG Therapeutics
6.17 CTI BioPharma
6.18 Intas Pharmaceuticals
6.19 Kyowa Hakko Kirin

7 CANCER MONOCLONAL ANTIBODIES MANUFACTURING COST ANALYSIS

7.1 Cancer Monoclonal Antibodies Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Cancer Monoclonal Antibodies

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Cancer Monoclonal Antibodies Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Cancer Monoclonal Antibodies Major Manufacturers in 2016
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 EMEA CANCER MONOCLONAL ANTIBODIES MARKET FORECAST (2017-2022)

11.1 EMEA Cancer Monoclonal Antibodies Sales, Revenue and Price Forecast (2017-2022)
  11.1.1 EMEA Cancer Monoclonal Antibodies Sales and Growth Rate Forecast (2017-2022)
  11.1.2 EMEA Cancer Monoclonal Antibodies Revenue and Growth Rate Forecast (2017-2022)
  11.1.3 EMEA Cancer Monoclonal Antibodies Price and Trend Forecast (2017-2022)
11.2 EMEA Cancer Monoclonal Antibodies Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.3 Europe Cancer Monoclonal Antibodies Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.4 Middle Eastt Cancer Monoclonal Antibodies Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.5 Africa Cancer Monoclonal Antibodies Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.6 EMEA Cancer Monoclonal Antibodies Sales Forecast by Type (2017-2022)
11.7 EMEA Cancer Monoclonal Antibodies Sales Forecast by Application (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer

The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Product Picture of Cancer Monoclonal Antibodies
Figure EMEA Cancer Monoclonal Antibodies Sales Volume (K Units) by Type (2012-2022)
Figure EMEA Cancer Monoclonal Antibodies Sales Volume Market Share by Type (Product Category) in 2016
Figure Naked mAbs Product Picture
Figure Conjugated mAbs Product Picture
Figure EMEA Cancer Monoclonal Antibodies Sales Volume (K Units) by Application (2012-2022)
Figure EMEA Sales Market Share of Cancer Monoclonal Antibodies by Application in 2016
Figure Hospitals Examples
Table Key Downstream Customer in Hospitals
Figure Retail Pharmacies Examples
Table Key Downstream Customer in Retail Pharmacies
Figure EMEA Cancer Monoclonal Antibodies Market Size (Million USD) by Region (2012-2022)
Figure Europe Cancer Monoclonal Antibodies Revenue (Million USD) and Growth Rate (2012-2022)
Figure Europe Cancer Monoclonal Antibodies Revenue (Million USD) Status and Forecast by Countries
Figure Middle East Cancer Monoclonal Antibodies Revenue (Million USD) and Growth Rate (2012-2022)
Figure Middle East Cancer Monoclonal Antibodies Revenue (Million USD) Status and Forecast by Countries
Figure Africa Cancer Monoclonal Antibodies Revenue (Million USD) and Growth Rate (2012-2022)
Figure Africa Cancer Monoclonal Antibodies Revenue (Million USD) Status and Forecast by Countries
Figure EMEA Cancer Monoclonal Antibodies Sales Volume and Growth Rate (2012-2022)
Figure EMEA Cancer Monoclonal Antibodies Revenue (Million USD) and Growth Rate (2012-2022)
Figure EMEA Cancer Monoclonal Antibodies Market Major Players Product Sales Volume (K Units) (2012-2017)
Table EMEA Cancer Monoclonal Antibodies Sales Volume (K Units) of Major Players (2012-2017)
Table EMEA Cancer Monoclonal Antibodies Sales Share by Players (2012-2017)
Figure 2016 Cancer Monoclonal Antibodies Sales Share by Players
Figure 2017 Cancer Monoclonal Antibodies Sales Share by Players
Figure EMEA Cancer Monoclonal Antibodies Market Major Players Product Revenue (Million USD) (2012-2017)
Table EMEA Cancer Monoclonal Antibodies Revenue (Million USD) by Players (2012-2017)
Table EMEA Cancer Monoclonal Antibodies Revenue Share by Players (2012-2017)
Table 2016 EMEA Cancer Monoclonal Antibodies Revenue Share by Players
Table 2017 EMEA Cancer Monoclonal Antibodies Revenue Share by Players
Table EMEA Cancer Monoclonal Antibodies Sale Price (USD/Unit) by Players (2012-2017)
Table EMEA Cancer Monoclonal Antibodies Sales (K Units) and Market Share by Type (2012-2017)
Table EMEA Cancer Monoclonal Antibodies Sales Share by Type (2012-2017)
Figure Sales Market Share of Cancer Monoclonal Antibodies by Type (2012-2017)
Figure EMEA Cancer Monoclonal Antibodies Sales Market Share by Type (2012-2017)
Table EMEA Cancer Monoclonal Antibodies Revenue (Million USD) and Market Share by Type (2012-2017)
Table EMEA Cancer Monoclonal Antibodies Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Cancer Monoclonal Antibodies by Type in 2016
Table EMEA Cancer Monoclonal Antibodies Sale Price (USD/Unit) by Type (2012-2017)
Table EMEA Cancer Monoclonal Antibodies Sales (K Units) and Market Share by Application (2012-2017)
Table EMEA Cancer Monoclonal Antibodies Sales Share by Application (2012-2017)
Figure Sales Market Share of Cancer Monoclonal Antibodies by Application (2012-2017)
Figure EMEA Cancer Monoclonal Antibodies Sales Market Share by Application in 2016
Table EMEA Cancer Monoclonal Antibodies Sales (K Units) and Market Share by Region (2012-2017)
Table EMEA Cancer Monoclonal Antibodies Sales Share by Region (2012-2017)
Figure Sales Market Share of Cancer Monoclonal Antibodies by Region (2012-2017)
Figure EMEA Cancer Monoclonal Antibodies Sales Market Share in 2016
Table EMEA Cancer Monoclonal Antibodies Revenue (Million USD) and Market Share by Region (2012-2017)
Table EMEA Cancer Monoclonal Antibodies Revenue Share by Region (2012-2017)
Figure Revenue Market Share of Cancer Monoclonal Antibodies by Region (2012-2017)
Figure EMEA Cancer Monoclonal Antibodies Revenue Market Share Regions in 2016
Table EMEA Cancer Monoclonal Antibodies Sales Price (USD/Unit) by Region (2012-2017)
Figure Europe Cancer Monoclonal Antibodies Sales (K Units) and Growth Rate (2012-2017)
Figure Europe Cancer Monoclonal Antibodies Revenue and Growth Rate (2012-2017)
Table Europe Cancer Monoclonal Antibodies Sales (K Units) by Type (2012-2017)
Table Europe Cancer Monoclonal Antibodies Market Share by Type (2012-2017)
Figure Europe Cancer Monoclonal Antibodies Market Share by Type in 2016
Table Europe Cancer Monoclonal Antibodies Sales (K Units) by Application (2012-2017)
Table Europe Cancer Monoclonal Antibodies Market Share by Application (2012-2017)
Figure Europe Cancer Monoclonal Antibodies Market Share by Application in 2016
Table Europe Cancer Monoclonal Antibodies Sales (K Units) by Countries (2012-2017)
Table Europe Cancer Monoclonal Antibodies Sales Market Share by Countries (2012-2017)
Figure Europe Cancer Monoclonal Antibodies Sales Market Share by Countries (2012-2017)
Figure Europe Cancer Monoclonal Antibodies Sales Market Share by Countries in 2016
Table Europe Cancer Monoclonal Antibodies Revenue (Million USD) by Countries (2012-2017)
Table Europe Cancer Monoclonal Antibodies Revenue Market Share by Countries (2012-2017)
Figure Europe Cancer Monoclonal Antibodies Revenue Market Share by Countries (2012-2017)
Figure Europe Cancer Monoclonal Antibodies Revenue Market Share by Countries in 2016
Figure Germany Cancer Monoclonal Antibodies Sales (K Units) and Growth Rate (2012-2017)
Figure France Cancer Monoclonal Antibodies Sales (K Units) and Growth Rate (2012-2017)
Figure UK Cancer Monoclonal Antibodies Sales (K Units) and Growth Rate (2012-2017)
Figure Russia Cancer Monoclonal Antibodies Sales (K Units) and Growth Rate (2012-2017)
Figure Italy Cancer Monoclonal Antibodies Sales (K Units) and Growth Rate (2012-2017)
Figure Benelux Cancer Monoclonal Antibodies Sales (K Units) and Growth Rate (2012-2017)
Figure Middle East Cancer Monoclonal Antibodies Sales (K Units) and Growth Rate (2012-2017)
Figure Middle East Cancer Monoclonal Antibodies Revenue (Million USD) and Growth Rate (2012-2017)
Table Middle East Cancer Monoclonal Antibodies Sales (K Units) by Type (2012-2017)
Table Middle East Cancer Monoclonal Antibodies Market Share by Type (2012-2017)
Figure Middle East Cancer Monoclonal Antibodies Market Share by Type (2012-2017)
Table Middle East Cancer Monoclonal Antibodies Sales (K Units) by Applications (2012-2017)
Table Middle East Cancer Monoclonal Antibodies Market Share by Applications (2012-2017)
Figure Middle East Cancer Monoclonal Antibodies Sales Market Share by Application in 2016
Table Middle East Cancer Monoclonal Antibodies Sales Volume (K Units) by Countries (2012-2017)
Table Middle East Cancer Monoclonal Antibodies Sales Volume Market Share by Countries (2012-2017)
Figure Middle East Cancer Monoclonal Antibodies Sales Volume Market Share by Countries in 2016
Table Middle East Cancer Monoclonal Antibodies Revenue (Million USD) by Countries (2012-2017)
Table Middle East Cancer Monoclonal Antibodies Revenue Market Share by Countries (2012-2017)
Figure Middle East Cancer Monoclonal Antibodies Revenue Market Share by Countries (2012-2017)
Figure Middle East Cancer Monoclonal Antibodies Revenue Market Share by Countries in 2016
Figure Saudi Arabia Cancer Monoclonal Antibodies Sales (K Units) and Growth Rate (2012-2017)
Figure Israel Cancer Monoclonal Antibodies Sales (K Units) and Growth Rate (2012-2017)
Figure UAE Cancer Monoclonal Antibodies Sales (K Units) and Growth Rate (2012-2017)
Figure Iran Cancer Monoclonal Antibodies Sales (K Units) and Growth Rate (2012-2017)
Figure Africa Cancer Monoclonal Antibodies Sales (K Units) and Growth Rate (2012-2017)
Figure Africa Cancer Monoclonal Antibodies Revenue (Million USD) and Growth Rate (2012-2017)
Table Africa Cancer Monoclonal Antibodies Sales (K Units) by Type (2012-2017)
Table Africa Cancer Monoclonal Antibodies Sales Market Share by Type (2012-2017)
Figure Africa Cancer Monoclonal Antibodies Sales Market Share by Type (2012-2017)
Figure Africa Cancer Monoclonal Antibodies Sales Market Share by Type in 2016
Table Africa Cancer Monoclonal Antibodies Sales (K Units) by Application (2012-2017)
Table Africa Cancer Monoclonal Antibodies Sales Market Share by Application (2012-2017)
Figure Africa Cancer Monoclonal Antibodies Sales Market Share by Application (2012-2017)
Table Africa Cancer Monoclonal Antibodies Sales Volume (K Units) by Countries (2012-2017)
Table Africa Cancer Monoclonal Antibodies Sales Market Share by Countries (2012-2017)
Figure Africa Cancer Monoclonal Antibodies Sales Market Share by Countries (2012-2017)
Figure Africa Cancer Monoclonal Antibodies Sales Market Share by Countries in 2016
Table Africa Cancer Monoclonal Antibodies Revenue (Million USD) by Countries (2012-2017)
Table Africa Cancer Monoclonal Antibodies Revenue Market Share by Countries (2012-2017)
Figure Africa Cancer Monoclonal Antibodies Revenue Market Share by Countries (2012-2017)
Figure Africa Cancer Monoclonal Antibodies Revenue Market Share by Countries in 2016
Figure South Africa Cancer Monoclonal Antibodies Sales (K Units) and Growth Rate (2012-2017)
Figure Nigeria Cancer Monoclonal Antibodies Sales (K Units) and Growth Rate (2012-2017)
Figure Egypt Cancer Monoclonal Antibodies Sales (K Units) and Growth Rate (2012-2017)
Figure Algeria Cancer Monoclonal Antibodies Sales (K Units) and Growth Rate (2012-2017)
Table F. Hoffmann-La Roche Cancer Monoclonal Antibodies Basic Information List
Table F. Hoffmann-La Roche Cancer Monoclonal Antibodies Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure F. Hoffmann-La Roche Cancer Monoclonal Antibodies Sales (K Units) and Growth Rate (2012-2017)
Figure F. Hoffmann-La Roche Cancer Monoclonal Antibodies Sales Market Share in EMEA (2012-2017)
Figure F. Hoffmann-La Roche Cancer Monoclonal Antibodies Revenue Market Share in EMEA (2012-2017)
Table Amgen Cancer Monoclonal Antibodies Basic Information List
Table Amgen Cancer Monoclonal Antibodies Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Amgen Cancer Monoclonal Antibodies Sales (K Units) and Growth Rate (2012-2017)
Figure Amgen Cancer Monoclonal Antibodies Sales Market Share in EMEA (2012-2017)
Figure Amgen Cancer Monoclonal Antibodies Revenue Market Share in EMEA (2012-2017)
Table Bristol-Myers Squibb Cancer Monoclonal Antibodies Basic Information List
Table Bristol-Myers Squibb Cancer Monoclonal Antibodies Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Bristol-Myers Squibb Cancer Monoclonal Antibodies Sales (K Units) and Growth Rate (2012-2017)
Figure Bristol-Myers Squibb Cancer Monoclonal Antibodies Sales Market Share in EMEA (2012-2017)
Figure Bristol-Myers Squibb Cancer Monoclonal Antibodies Revenue Market Share in EMEA (2012-2017)
Table Takeda Pharmaceuticals Cancer Monoclonal Antibodies Basic Information List
Table Takeda Pharmaceuticals Cancer Monoclonal Antibodies Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Takeda Pharmaceuticals Cancer Monoclonal Antibodies Sales (K Units) and Growth Rate (2012-2017)
Figure Takeda Pharmaceuticals Cancer Monoclonal Antibodies Sales Market Share in EMEA (2012-2017)
Figure Takeda Pharmaceuticals Cancer Monoclonal Antibodies Revenue Market Share in EMEA (2012-2017)
Table Pfizer Cancer Monoclonal Antibodies Basic Information List
Table Pfizer Cancer Monoclonal Antibodies Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Pfizer Cancer Monoclonal Antibodies Sales (K Units) and Growth Rate (2012-2017)
Figure Pfizer Cancer Monoclonal Antibodies Sales Market Share in EMEA (2012-2017)
Figure Pfizer Cancer Monoclonal Antibodies Revenue Market Share in EMEA (2012-2017)
Table Merck Cancer Monoclonal Antibodies Basic Information List
Table Merck Cancer Monoclonal Antibodies Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Merck Cancer Monoclonal Antibodies Sales (K Units) and Growth Rate (2012-2017)
Figure Merck Cancer Monoclonal Antibodies Sales Market Share in EMEA (2012-2017)
Figure Merck Cancer Monoclonal Antibodies Revenue Market Share in EMEA (2012-2017)
Table Eli Lilly Cancer Monoclonal Antibodies Basic Information List
Table Eli Lilly Cancer Monoclonal Antibodies Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Eli Lilly Cancer Monoclonal Antibodies Sales (K Units) and Growth Rate (2012-2017)
Figure Eli Lilly Cancer Monoclonal Antibodies Sales Market Share in EMEA (2012-2017)
Figure Eli Lilly Cancer Monoclonal Antibodies Revenue Market Share in EMEA (2012-2017)
Table Sanofi Cancer Monoclonal Antibodies Basic Information List
Table Sanofi Cancer Monoclonal Antibodies Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Sanofi Cancer Monoclonal Antibodies Sales (K Units) and Growth Rate (2012-2017)
Figure Sanofi Cancer Monoclonal Antibodies Sales Market Share in EMEA (2012-2017)
Figure Sanofi Cancer Monoclonal Antibodies Revenue Market Share in EMEA (2012-2017)
Table Janssen Biotech Cancer Monoclonal Antibodies Basic Information List
Table Janssen Biotech Cancer Monoclonal Antibodies Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Janssen Biotech Cancer Monoclonal Antibodies Sales (K Units) and Growth Rate (2012-2017)
Figure Janssen Biotech Cancer Monoclonal Antibodies Sales Market Share in EMEA (2012-2017)
Figure Janssen Biotech Cancer Monoclonal Antibodies Revenue Market Share in EMEA (2012-2017)
Table Novartis Cancer Monoclonal Antibodies Basic Information List
Table Novartis Cancer Monoclonal Antibodies Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Novartis Cancer Monoclonal Antibodies Sales (K Units) and Growth Rate (2012-2017)
Figure Novartis Cancer Monoclonal Antibodies Sales Market Share in EMEA (2012-2017)
Figure Novartis Cancer Monoclonal Antibodies Revenue Market Share in EMEA (2012-2017)
Table AbbVie Cancer Monoclonal Antibodies Basic Information List
Table Boehringer Ingelheim Cancer Monoclonal Antibodies Basic Information List
Table AstraZeneca Cancer Monoclonal Antibodies Basic Information List
Table Bayer Cancer Monoclonal Antibodies Basic Information List
Table Biogen Cancer Monoclonal Antibodies Basic Information List
Table TG Therapeutics Cancer Monoclonal Antibodies Basic Information List
Table CTI BioPharma Cancer Monoclonal Antibodies Basic Information List
Table Intas Pharmaceuticals Cancer Monoclonal Antibodies Basic Information List
Table Kyowa Hakko Kirin Cancer Monoclonal Antibodies Basic Information List
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Cancer Monoclonal Antibodies
Figure Manufacturing Process Analysis of Cancer Monoclonal Antibodies
Figure Cancer Monoclonal Antibodies Industrial Chain Analysis
Table Raw Materials Sources of Cancer Monoclonal Antibodies Major Manufacturers in 2016
Table Major Buyers of Cancer Monoclonal Antibodies
Table Distributors/Traders List
Figure EMEA Cancer Monoclonal Antibodies Sales (K Units) and Growth Rate Forecast (2017-2022)
Figure EMEA Cancer Monoclonal Antibodies Revenue and Growth Rate Forecast (2017-2022)
Figure EMEA Cancer Monoclonal Antibodies Price (USD/Unit) and Trend Forecast (2017-2022)
Table EMEA Cancer Monoclonal Antibodies Sales (K Units) Forecast by Region (2017-2022)
Figure EMEA Cancer Monoclonal Antibodies Sales Market Share Forecast by Region (2017-2022)
Table EMEA Cancer Monoclonal Antibodies Revenue (Million USD) Forecast by Region (2017-2022)
Figure EMEA Cancer Monoclonal Antibodies Revenue Market Share Forecast by Region (2017-2022)
Table Europe Cancer Monoclonal Antibodies Sales (K Units) Forecast by Countries (2017-2022)
Figure Europe Cancer Monoclonal Antibodies Sales Market Share Forecast by Countries (2017-2022)
Table Europe Cancer Monoclonal Antibodies Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Europe Cancer Monoclonal Antibodies Revenue Market Share Forecast by Countries (2017-2022)
Table Middle East Cancer Monoclonal Antibodies Sales (K Units) Forecast by Countries (2017-2022)
Figure Middle East Cancer Monoclonal Antibodies Sales Market Share Forecast by Countries (2017-2022)
Table Middle East Cancer Monoclonal Antibodies Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Middle East Cancer Monoclonal Antibodies Revenue Market Share Forecast by Countries (2017-2022)
Table Africa Cancer Monoclonal Antibodies Sales (K Units) Forecast by Countries (2017-2022)
Figure Africa Cancer Monoclonal Antibodies Sales Market Share Forecast by Countries (2017-2022)
Table Africa Cancer Monoclonal Antibodies Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Africa Cancer Monoclonal Antibodies Revenue Market Share Forecast by Countries (2017-2022)
Table EMEA Cancer Monoclonal Antibodies Sales (K Units) Forecast by Type (2017-2022)
Figure EMEA Cancer Monoclonal Antibodies Sales Market Share Forecast by Type (2017-2022)
Table EMEA Cancer Monoclonal Antibodies Sales (K Units) Forecast by Application (2017-2022)
Figure EMEA Cancer Monoclonal Antibodies Sales Market Share Forecast by Application (2017-2022)
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources